




The relative strengths and weaknesses of Urogen Pharma Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urogen Pharma Ltd compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 9.1% points. The greatest weakness of Urogen Pharma Ltd is the variable Stockholders Equity, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 86% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	169,186
Cost of Goods Sold	9,361
Intangible Assets	0
Liabilities, Current	31,212
Liabilities, Non-Current	99,395
Other Assets	8,436
Other Compr. Net Income	119
Other Expenses	40,187
Other Liabilities	112,916
Other Net Income	3,479
Other Revenues	82,713
Property and Equipment	689
Research and Development	45,614
Selling, General and Administrative Expense	93,274

Output Variable	Value in 1000 USD
Assets	178,311
Liabilities	243,523
Expenses	188,436
Revenues	82,713
Stockholders Equity	-65,212
Net Income	-102,244
Comprehensive Net Income	-102,184
BaseVar	348,290
ECR before LimitedLiability	-116%
Economic Capital Ratio	127%